சுகாதாரம் தொழில்நுட்பங்கள் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சுகாதாரம் தொழில்நுட்பங்கள் நிறுவனம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சுகாதாரம் தொழில்நுட்பங்கள் நிறுவனம் Today - Breaking & Trending Today

New Approach for Anti-fibrotic Therapy for Glaucoma Labmate Online

Jan 14 2021 Read 266 Times
University of Birmingham (UK) scientists have shown that a novel low molecular weight dextran-sulphate, ILB® could play a key role in treating open angle glaucoma (OAG), a neurodegenerative disease, affecting over 70 million people worldwide, by lowering increased intraocular pressure (IOP) within the eye’s main fluid drainage site.,
OAG develops slowly over many years, leading to excessive matrix deposition (fibrosis), which in turn can lead to increased intraocular pressure (IOP), causing damage to the optic nerve and blindness.
The research has shown that that ILB can normalise matrix deposition inside the eye in a pre-clinical model used to mimic these aspects of human glaucoma, paving the way for new anti-fibrotic therapies to be developed for the disease. ....

Imran Masood , Hannah Botfield , Lisa Hill , University Healthcare Technologies Institute , Institute Of Clinical Sciences , University Of Birmingham United Kingdom , Institute Of Inflammation , United Kingdom , Transforming Growth Factor , Clinical Sciences , West Birmingham , Professor Liam Grover , Healthcare Technologies Institute , இம்ரான் மசூட் , லிசா மலை , பல்கலைக்கழகம் சுகாதாரம் தொழில்நுட்பங்கள் நிறுவனம் , நிறுவனம் ஆஃப் மருத்துவ அறிவியல் , பல்கலைக்கழகம் ஆஃப் பர்மிங்காம் ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது கிஂக்டம் , மாற்றும் வளர்ச்சி காரணி , மருத்துவ அறிவியல் , மேற்கு பர்மிங்காம் , ப்ரொஃபெஸர் லியாம் தோப்பு , சுகாதாரம் தொழில்நுட்பங்கள் நிறுவனம் ,

Novel low molecular weight dextran-sulphate could play a key role in glaucoma treatment

Novel low molecular weight dextran-sulphate could play a key role in glaucoma treatment
Scientists at the University of Birmingham, UK, have shown that a novel low molecular weight dextran-sulphate, ILB
® could play a key role in treating open angle glaucoma (OAG), a neurodegenerative disease that affects over 70 million people worldwide and causes irreversible blindness.
OAG develops slowly over many years. Excessive matrix deposition (fibrosis) within the eye s main fluid drainage site can lead to increased intraocular pressure (IOP), resulting in damage to the optic nerve.
The research, reported in npj Regenerative Medicine, has shown that that ILB can normalize matrix deposition inside the eye and lower IOP in a pre-clinical model used to mimic these aspects of human glaucoma, paving the way for new anti-fibrotic therapies to be developed for the disease. ....

United Kingdom , Imran Masood , Hannah Botfield , Lisa Hill , Emily Henderson , University Healthcare Technologies Institute , Institute Of Clinical Sciences , University Of Birmingham , Institute Of Inflammation , Regenerative Medicine , Transforming Growth Factor , Clinical Sciences , West Birmingham , Professor Liam Grover , Healthcare Technologies Institute , ஒன்றுபட்டது கிஂக்டம் , இம்ரான் மசூட் , லிசா மலை , எமிலி ஹென்டர்சன் , பல்கலைக்கழகம் சுகாதாரம் தொழில்நுட்பங்கள் நிறுவனம் , நிறுவனம் ஆஃப் மருத்துவ அறிவியல் , பல்கலைக்கழகம் ஆஃப் பர்மிங்காம் , மீளுருவாக்கம் மருந்து , மாற்றும் வளர்ச்சி காரணி , மருத்துவ அறிவியல் , மேற்கு பர்மிங்காம் ,

Sorrento Therapeutics developing antibodies injection and nose drops to fight Covid-19

Sorrento Therapeutics developing antibodies injection and nose drops to fight Covid-19
CNBC
12/23/2020
Sorrento Therapeutics is working on new antibody therapeutics in the fight against Covid-19.
It won a $34 million contract from DARPA co-funded by JPEO to develop an intramuscular injection that delivers gene-encoded neutralizing antibodies against Covid-19 and its variant strains.
The company filed an investigational new drug application with the FDA for a Phase 1 clinical trial to test the safety and efficacy of COVI-DROPS, antibody nose drops that it claims boosts immunity against Covid-19 by blocking the infection and spread of the virus.
© Provided by CNBC
Medical staff member Christina Mathers attends to a patient, who is unconscious, as she holds the patient s hand in the COVID-19 intensive care unit (ICU) at the United Memorial Medical Center on December 21, 2020 in Houston, Texas. ....

United States , San Diego , University Of Texas , Moncef Slaoui , Henry Ji , Donald Trump , Christina Mathers , Eli Lilly , Slobodan Paessler , Healthcare Technologies Institute , Animal Biosafety Laboratory , United Memorial Medical Center On , University Of Birmingham , University Of Texas Medical Branch , John Hopkins University , University Of Pennsylvania , Sorrento Therapeutics , United Memorial Medical Center , Smartpharm Therapeutics , Texas Medical Branch , John Hopkins , Chief Executive Officer , Operation Warp Speed , Auris Medical , President Donald , ஒன்றுபட்டது மாநிலங்களில் ,